Skip to content
value.today
Atea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc.

Total raised
$176 M
4 rounds on record
Latest round
$108 M
May 2020
First round on record
Dec 2013
Today
Went public
See the company page

Atea Pharmaceuticals, Inc. is listed today as Atea Pharmaceuticals, Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Atea Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2020$108 MNo. 4$50 to $250 million

Atea Pharmaceuticals, Inc.: Raise no. 4, May 2020

Investors in this round

37 investors had bought by the notice of May 29, 2020: 37 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Atea Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$108 M of $215 M offered; $108 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$500,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrea Corcoran · Executive Officer
  • Jean-Pierre Sommadossi, Ph.D. · Executive Officer, Director
  • Andrew Hack, M.D., Ph.D. · Director
  • Bihua Chen · Director
  • Bruce Polsky · Director
  • Bruno Lucidi · Director
  • Franklin Berger · Director
  • Grigory Borisenko · Director
  • Isaac Cheng, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • William Blair (CRD 1252) · Chicago, IllinoisSold in all US states

Signed by Jean-Pierre Sommadossi, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 29, 2020. Read the notice at the SEC.

equitySEC
Jun 2018$28 MNo. 3$10 to $50 million

Atea Pharmaceuticals, Inc.: Raise no. 3, Jun 2018

Investors in this round

38 investors had bought by the notice of Jul 16, 2018: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Atea Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$28 M of $28 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$119,499
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrea Corcoran · Executive Officer
  • Jean-Pierre Sommadossi · Executive Officer, Director
  • Bihua Chen · Director
  • Bruce Polsky · Director
  • Bruno Lucidi · Director
  • Evgeny Zatsev · Director
  • Fan Yu · Director
  • Gerald Chan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • CIM Securities, LLC (CRD 120852) · Centennial, ColoradoSold in AZ, CO, MA, NV, NY, PA, TX, WA

Signed by Jean-Pierre Sommadossi, CEO and President. Source: SEC Form D, newest notice filed Jul 16, 2018. Read the notice at the SEC.

equitySEC
Aug 2016$21 MNo. 2$10 to $50 million

Atea Pharmaceuticals, Inc.: Raise no. 2, Aug 2016

Investors in this round

29 investors had bought by the notice of Sep 13, 2016: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Atea Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$21 M of $21 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$167,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jean-Pierre Sommadossi, Ph.D. · Executive Officer, Director
  • Bruce Polsky · Director
  • Bruno Lucidi · Director
  • Evgeny Zatsev · Director
  • Frank Yu · Director
  • Gerald Chan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Sinh Ly · broker-dealer CIM Securities (CRD 120852) · Centennial, ColoradoSold in AL, CA, CO, CT, FL, IL, MI, NJ, NV, OR, SC, TX

Signed by Jean-Pierre Sommadossi, CEO and President. Source: SEC Form D, newest notice filed Sep 13, 2016. Read the notice at the SEC.

equitySEC
Dec 2013$20 MNo. 1$10 to $50 million

Atea Pharmaceuticals, Inc.: Raise no. 1, Dec 2013

Investors in this round

59 investors had bought by the notice of Sep 17, 2014: 59 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for Atea Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$811,098
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jean-Pierre Sommadossi, Ph.D. · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Madding King · broker-dealer Brookline Group, LLC (CRD 153587) · Birmingham, AlabamaSold in AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, ID, IL, IN, KS, LA, MA, MD, ME, MI, MN, MO, MS, NC, NE, NJ, NM, NV, NY, OH, OK, OR, PA, RI, SC, TN, TX, UT, VA, WA, WI, WV, WY

Remarks in the notice

  • On fees: “Total sales commission includes reimbursement of fees and issuance of of 557,100 shares of common stock.”

Signed by Jean-Pierre Sommadossi, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Sep 17, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Atea Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (May 2020).

    SEC Form D · May 2020

  • The industry group it chose in its notices: Other.

    SEC Form D · May 2020

That is all the official record says: Atea Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Atea Pharmaceuticals, Inc. are on record.

Investors#

10 named in official filings. Open an investor to see everything it has backed.

Investors in Atea Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
Andrea CorcoranPersonnot statednot statedHeld Series A and B preferred stock (Form 3, 2020)SEC Form 3
Chung K. ChuPersonnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Cormorant Asset Management, LPFund or asset managernot statednot statedHeld Series A, B, C, D and D-1 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Cormorant Private Healthcare Fund II, LPFund or asset managernot statednot statedHeld Series A, B, C, D and D-1 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Cormorant Private Healthcare Fund I, LPFund or asset managernot statednot statedHeld Series A, B, C, D and D-1 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Franklin M. BergerPersonnot statednot statedHeld Series A, B, C, D and D-1 preferred stock, director (Form 3, 2020)SEC Form 3
JPM Partners LLCFund or asset managernot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Rock Springs Capital LLCFund or asset managernot statednot statedHeld Series D and D-1 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Rock Springs Capital Management LPFund or asset managernot statednot statedHeld Series D and D-1 preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Rock Springs Capital Master Fund LPFund or asset managernot statednot statedHeld Series D and D-1 preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 59 investors.

Largest shareholders today

Institutions holding Atea Pharmaceuticals, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Atea Pharmaceuticals, Inc.
NameRoleNamed in
Andrea CorcoranExecutive officerMay 2020
Jean-Pierre Sommadossi, Ph.D.Executive officerMay 2020
Jean-Pierre SommadossiExecutive officerJul 2018
Andrew Hack, M.D., Ph.D.DirectorMay 2020
Bihua ChenDirectorMay 2020
Bruce PolskyDirectorMay 2020
Bruno LucidiDirectorMay 2020
Franklin BergerDirectorMay 2020
Grigory BorisenkoDirectorMay 2020
Isaac Cheng, M.D.DirectorMay 2020
Jean-Pierre Sommadossi, Ph.D.DirectorMay 2020
Evgeny ZatsevDirectorJul 2018
Fan YuDirectorJul 2018
Gerald ChanDirectorJul 2018
Jean-Pierre SommadossiDirectorJul 2018
Frank YuDirectorSep 2016

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.